Park Ha Biological Technology Co., Ltd. income statement

In fiscal 2025, Park Ha Biological Technology Co., Ltd. reported revenue of $2.5m, up 6.0% on the year before, operating income of −$24.1m (a -956.5% margin) and net income of −$24.4m, or −$41.38 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Park Ha Biological Technology Co., Ltd.: income statement, annual
Fiscal year	2022Oct 2022	2023Oct 2023	2024Oct 2024	2025Oct 2025
Revenue	2	2	2	3
Cost of revenue	1	0	0	0
Gross profit	1	2	2	2
Research and development	0	0	0	0
Selling and marketing	0	0	0	1
General and administrative	1	0	1	25
Operating income	0	1	1	−24
Interest expense	0	—	—	0
Provision for credit losses	—	—	−0	0
Income before tax	0	1	1	−24
Income tax	−0	0	0	0
Net income	0	1	0	−24
Diluted EPS	$0.50	$1.70	$0.96	−$41.38
Diluted shares (average)	—	—	—	—
EBITDA	0	1	1	−24

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BYAH vs SNES BYAH vs ZONE BYAH vs CITR BYAH vs REFR

More: Specialty Chemicals stocks compared, Materials sector, rankings of US companies

Figures from Park Ha Biological Technology Co., Ltd.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Park Ha Biological Technology Co., Ltd.